Expression of Serpin B9 as a Prognostic Factor of Colorectal Cancer
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F19%3A10400052" target="_blank" >RIV/00216208:11140/19:10400052 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00669806:_____/19:10400052
Výsledek na webu
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=MHETjU-Enw" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=MHETjU-Enw</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.21873/anticanres.13813" target="_blank" >10.21873/anticanres.13813</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Expression of Serpin B9 as a Prognostic Factor of Colorectal Cancer
Popis výsledku v původním jazyce
BACKGROUND/AIM: Treatment of colorectal cancer (CRC) does not reflect immune interactions between tumours and macro-organisms. Serpin B9 is known as an inhibitor of Granzyme B. The aim of this study was to evaluate the impact of the expression of Serpin B9 in CRC and healthy colon tissue on prognosis. PATIENTS AND METHODS: This retrospective study included 74 CRC patients in all stages. Analysis of gene expression was performed with quantitative polymerase chain reaction with reverse transcription using specific primers and master mix Xceed qPCR SG. Expression was normalized to the reference genes GAPDH, ACTB, and PSMC. RESULTS: Increased expression of Serpin B9 in healthy tissue was significantly associated with longer overall survival (OS). This association was found both in all patients and in the group of patients with distant metastases. CONCLUSION: The presented results support previous evidence of positive influence of the interaction between immune system and tumour on the prognosis of CRC. Copyright(C) 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Název v anglickém jazyce
Expression of Serpin B9 as a Prognostic Factor of Colorectal Cancer
Popis výsledku anglicky
BACKGROUND/AIM: Treatment of colorectal cancer (CRC) does not reflect immune interactions between tumours and macro-organisms. Serpin B9 is known as an inhibitor of Granzyme B. The aim of this study was to evaluate the impact of the expression of Serpin B9 in CRC and healthy colon tissue on prognosis. PATIENTS AND METHODS: This retrospective study included 74 CRC patients in all stages. Analysis of gene expression was performed with quantitative polymerase chain reaction with reverse transcription using specific primers and master mix Xceed qPCR SG. Expression was normalized to the reference genes GAPDH, ACTB, and PSMC. RESULTS: Increased expression of Serpin B9 in healthy tissue was significantly associated with longer overall survival (OS). This association was found both in all patients and in the group of patients with distant metastases. CONCLUSION: The presented results support previous evidence of positive influence of the interaction between immune system and tumour on the prognosis of CRC. Copyright(C) 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30204 - Oncology
Návaznosti výsledku
Projekt
Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Ostatní
Rok uplatnění
2019
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Anticancer Research
ISSN
0250-7005
e-ISSN
—
Svazek periodika
39
Číslo periodika v rámci svazku
11
Stát vydavatele periodika
GR - Řecká republika
Počet stran výsledku
4
Strana od-do
6063-6066
Kód UT WoS článku
000496129100025
EID výsledku v databázi Scopus
2-s2.0-85074687489